Multidisciplinary consensus statement on the clinical management of patients with pancreatic cancer

Martín-Pérez, Elena; Domínguez‐Muñoz, J. Enrique; Botella-Romero, Francisco; Cerezo, Laura; Teresa, F. Matute; Serrano, Teresa; Vera, Ruth

doi:10.1007/s12094-020-02350-6

Cited by 34 publications

(21 citation statements)

References 118 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Surgical resection remains the only chance of cure in PC; however, it represents an option in less than 20% of patients at diagnosis [69]. Neoadjuvant treatment may increase the resectability rate in borderline resectable (BRPC) and locally advanced (LAPC) at the cost of significant effects on body composition.…”

Section: Neoadjuvant and Preoperatory Settingmentioning

confidence: 99%

Clinical Implications of Malnutrition in the Management of Patients with Pancreatic Cancer: Introducing the Concept of the Nutritional Oncology Board

et al. 2021

View full text Add to dashboard Cite

Pancreatic cancer represents a very challenging disease, with an increasing incidence and an extremely poor prognosis. Peculiar features of this tumor entity are represented by pancreatic exocrine insufficiency and an early and intense nutritional imbalance, leading to the highly prevalent and multifactorial syndrome known as cancer cachexia. Recently, also the concept of sarcopenic obesity has emerged, making the concept of pancreatic cancer malnutrition even more multifaceted and complex. Overall, these nutritional derangements play a pivotal role in contributing to the dismal course of this malignancy. However, their relevance is often underrated and their assessment is rarely applied in clinical daily practice with relevant negative impact for patients’ outcome in neoadjuvant, surgical, and metastatic settings. The proper detection and management of pancreatic cancer-related malnutrition syndromes are of primary importance and deserve a specific and multidisciplinary (clinical nutrition, oncology, etc.) approach to improve survival, but also the quality of life. In this context, the introduction of a “Nutritional Oncology Board” in routine daily practice, aimed at assessing an early systematic screening of patients and at implementing nutritional support from the time of disease diagnosis onward seems to be the right path to take.

show abstract

Section: Neoadjuvant and Preoperatory Settingmentioning

confidence: 99%

Clinical Implications of Malnutrition in the Management of Patients with Pancreatic Cancer: Introducing the Concept of the Nutritional Oncology Board

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Approximately 30% of patients with PC present with locally advanced disease [46,47]. Systemic CT is considered the standard of care [48], keeping RT for some patients who do not develop distant metastases after several months of CT [49]. Although combined CT has shown a substantially improved survival, it is associated with many side effects leading to dose reduction, delays, or therapy discontinuation [50].…”

Section: Locally Advancedmentioning

confidence: 99%

Clinical nutrition as part of the treatment pathway of pancreatic cancer patients: an expert consensus

et al. 2021

Self Cite

View full text Add to dashboard Cite

Purpose Malnutrition is a common problem among pancreatic cancer (PC) patients that negatively impacts on their quality of life (QoL) and clinical outcomes. The main objective of this consensus is to address the role of Medical Nutrition Therapy (MNT) into the comprehensive therapeutic management of PC patients. Methods A Spanish multidisciplinary group of specialists from the areas of Medical Oncology; Radiation Oncology; Endocrinology and Nutrition; and General Surgery agreed to assess the role of MNT as part of the best therapeutic management of PC patients. Results The panel established different recommendations focused on nutritional screening and nutritional screening tools, MNT strategies according to PC status, and MNT in palliative treatment. Conclusions There is an unmet need to integrate nutritional therapy as a crucial part of the multimodal care process in PC patients. Health authorities, health care professionals, cancer patients, and their families should be aware of the relevance of nutritional status and MNT on clinical outcomes and QoL of PC patients.

show abstract

“…In the absence of novel diagnostic methods and/or treatments, PC is expected to become the second leading cause of cancer-related deaths by 2030[ 2 ]. Complete surgical resection is a potentially curative treatment, but 80%-85% of patients present with non-resectable disease at their diagnosis due to local invasion or distant metastasis[ 3 ]. An early diagnosis is crucial but is highly challenging due to the lack of specific symptoms during initial stages of the disease.…”

Section: Introductionmentioning

confidence: 99%

Liquid biopsy approach to pancreatic cancer

Perales

Torres

Jiménez-Luna

et al. 2021

WJGO

View full text Add to dashboard Cite

Pancreatic cancer (PC) continues to pose a major clinical challenge. There has been little improvement in patient survival over the past few decades, and it is projected to become the second leading cause of cancer mortality by 2030. The dismal 5-year survival rate of less than 10% after the diagnosis is attributable to the lack of early symptoms, the absence of specific biomarkers for an early diagnosis, and the inadequacy of available chemotherapies. Most patients are diagnosed when the disease has already metastasized and cannot be treated. Cancer interception is vital, actively intervening in the malignization process before the development of a full-blown advanced tumor. An early diagnosis of PC has a dramatic impact on the survival of patients, and improved techniques are urgently needed to detect and evaluate this disease at an early stage. It is difficult to obtain tissue biopsies from the pancreas due to its anatomical position; however, liquid biopsies are readily available and can provide useful information for the diagnosis, prognosis, stratification, and follow-up of patients with PC and for the design of individually tailored treatments. The aim of this review was to provide an update of the latest advances in knowledge on the application of carbohydrates, proteins, cell-free nucleic acids, circulating tumor cells, metabolome compounds, exosomes, and platelets in blood as potential biomarkers for PC, focusing on their clinical relevance and potential for improving patient outcomes.

show abstract

Multidisciplinary consensus statement on the clinical management of patients with pancreatic cancer

Cited by 34 publications

References 118 publications

Clinical Implications of Malnutrition in the Management of Patients with Pancreatic Cancer: Introducing the Concept of the Nutritional Oncology Board

Clinical Implications of Malnutrition in the Management of Patients with Pancreatic Cancer: Introducing the Concept of the Nutritional Oncology Board

Clinical nutrition as part of the treatment pathway of pancreatic cancer patients: an expert consensus

Liquid biopsy approach to pancreatic cancer

Contact Info

Product

Resources

About